Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hamadan University of Medical Science | OTHER |
| Tehran University of Medical Sciences | OTHER |
Not provided
Not provided
Not provided
Not provided
The objective of this project is to determine if in patients admitted to the hospital with septic shock (population), does treatment with a bundle including hydrocortisone, thiamine, and ascorbic acid improve in-hospital or 28-day mortality (primary outcomes) or surrogate markers of illness severity including: (1) ICU or hospital length-of-stay, (2) duration of invasive mechanical ventilation, (3) duration of vasopressor administration, (4) incidence and severity of ICU delirium, and (5) illness severity (secondary outcomes).
This trial is designed as a multi-center prospective, double-blinded, randomized controlled study. The objective of this project is to determine if in patients admitted to the hospital with septic shock (population), does treatment with a bundle including hydrocortisone, thiamine, and ascorbic acid improve in-hospital or 28-day mortality (primary outcomes) or surrogate markers of illness severity including: (1) ICU or hospital length-of-stay, (2) duration of invasive mechanical ventilation, (3) duration of vasopressor administration, (4) incidence and severity of ICU delirium, and (5) illness severity (secondary outcomes). The calculated sample size is 80. Subjects will be followed for 28 days or until hospital discharge.
Patients eligible for inclusion must be admitted with septic shock (as defined by SEPSIS-3) requiring vasopressors to maintain MAP ≥ 65 AND serum lactate level >2 mmol/L after adequate fluid resuscitation (generally recognized at 30 ml/kg crystalloid unless contraindicated as deemed by treating clinician) within the first three hours.
The exclusion criteria are: age < 18 years, pregnant, patients with limitation of care (i.e. do not resuscitate [DNR]), known Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency, and vasopressor use for > 24 hours prior to study enrollment.
Patients in Arm 1 will randomized to receive usual care + hydrocortisone, thiamine and ascorbic acid. Arm 2 will be randomized to receive usual care alone. Crossover is not allowed. If a patient is randomized into study Arm 2, the treating physician may decide to administer study medications if they feel it is in the best interest of the patient. In this case the patient will continue to be analyzed in their assigned arm on an intention to treat basis. Source of participants will be in-hospital and Emergency Department patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1: Intervention | Experimental | Arm will be those that are randomized to receive usual care plus hydrocortisone, thiamine and ascorbic acid. |
|
| Arm 2: Usual care | No Intervention | Arm will be those that are randomized to receive usual care alone. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| STASIS | Drug | Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge |
| Measure | Description | Time Frame |
|---|---|---|
| In-hospital or 28-day mortality rate | To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care versus standard care in septic shock confers an in-hospital and 28-day mortality benefit | 28 days or discharge (whichever comes first) |
| Measure | Description | Time Frame |
|---|---|---|
| Illness Severity (Change in SOFA Score) | To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock confers more rapid improvements in illness severity | 72 hours |
| Hospital length-of-stay ICU LOS Duration of intubation |
Not provided
Inclusion Criteria:
Septic shock admitted to the ICU within 24 hours as defined by SEPSIS-3
SEPSIS-3 defines septic shock as sepsis with the following criteria despite adequate fluid resuscitation:
Age ≥ 18 years
Non-pregnant
Ability to consent with medical capacity or legally authorized representative (LAR) consent
Exclusion Criteria:
Age < 18 years
Pregnant defined by negative serum HCG in all females
Patients with limitation of care (i.e. DNR)
Known G6PD deficiency
Excluding primary admission diagnosis including the following:
Prisoners
>1 episode of sepsis in hospital admission
Vasopressor use prior to randomization for more than 24 hours
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Amir Vahedian-Azimi, PhD | Contact | +98 919 6017 138 | amirvahedian63@gmail.com | |
| Andrew C Miller, MD | Contact | Taqwa1@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Amir Vahedian-Azimi, PhD | Baqiyatallah University of Medical Scienecs | Principal Investigator |
| Andrew C Miller, MD | East Carolina University | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012772 | Shock, Septic |
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
Not provided
Not provided
| ID | Term |
|---|---|
| C555654 | IbsC protein, E coli |
Not provided
Not provided
Not provided
A Prospective Parallel Randomized Controlled clinical Study
Not provided
Not provided
Not provided
To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock confers improved hospital length-of-stay metrics |
| 1 year or discharge (whichever comes first) |
| ICU length-of-stay | To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock confers improved ICU length-of-stay metrics | 90 days or discharge (whichever comes first) |
| Vasopressor duration (days) | To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock confers improvement in vasopressor requirements | 28 days or discharge (whichever comes first) |
| ICU delerium (CAM-ICU score) | To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock changes the incidence or severity of ICU delerium | 28 days or discharge (whichever comes first) |
| Mechanical ventilation | To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock changes the incidence or duration of invasive mechanical ventilation. | 28 days or discharge (whichever comes first) |
| Cardiac arrest | To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock changes the incidence of cardiac arrest or need for cardiopulmonary resuscitation | 28 days or discharge (whichever comes first) |
| Renal replacement therapy | o determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock changes the incidence of cardiac arrest or need for renal replacement therapy. | 28 days or discharge (whichever comes first) |
| C-reactive protein | To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock changes the biochemical profiling in septic patients including a more rapid improvement in C-reactive protein | 28 days or discharge (whichever comes first) |
| Procalcitonin | o determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care in septic shock changes the biochemical profiling in septic patients including a more rapid improvement in procalcitonin. | 28 days or discharge (whichever comes first) |
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |